Business Context and Reporting Period
Company: Rockwell Medical, Inc. (RMTI)
Filing Type: Form 8-K (Current Report)
Report Date: December 31, 2025
Event Date: December 31, 2025 (Amendment effective December 23, 2025)
The Company entered into a Second Amendment to its Amended and Restated Products Purchase Agreement with DaVita, Inc.
Key Financial Metrics
This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on a contractual amendment.
Material Changes
- Contract Extension: The term of the Products Purchase Agreement with DaVita, Inc. has been extended by one year, now expiring on December 31, 2026.
- Pricing Adjustment: The Amendment includes a price increase for products sold under the Agreement during the Extension Term.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the successful negotiation of an extension and price increase with a key customer, DaVita, Inc.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text beyond the standard implications of contract renewals.
Investor Verification Checklist
- Verify the specific percentage or dollar amount of the price increase for the Extension Term.
- Review the original September 18, 2023 Agreement and the March 31, 2025 amendment to understand the baseline terms.
- Assess the proportion of total revenue derived from DaVita, Inc. to gauge the materiality of this extension and price increase.
- Confirm if the price increase is retroactive to the effective date of December 23, 2025, or applies only to future shipments.